College of Pharmacy
Institute for Therapeutics Discovery & Development
Findings open new opportunities to seek BioB inhibitors to treat infections with M. tuberculosis and other pathogens.
Initial preclinical studies showed YCT-529 was 99% effective and 100% reversible with no side effects.